Serum MIF in Acute Kidney Injury

Medical University of Vienna

Status: Completed

Conditions: Acute Kidney Injury

Treatments: Other: Blood draw for measurement of MIF

Study type: Observational

Funder types: Other

Identifiers

NCT02352506

1680/2014

Details and patient eligibility

About

Acute kidney injury (AKI) is a common complication in critical care patients. Currently no parameters are available for early prognosis of AKI. Macrophage migration inhibitory factor (MIF) has been associated with AKI in clinical studies. The aim of this study is to evaluate the time course of MIF concentrations in patients with AKI.

Enrollment: 500 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Exclusion Criteria:

• Age < 18 years and > 80 years
• Patients with chronic dialysis
• Patients with continuous hemodialysis, hemofiltration or hemodiafiltration within 4 weeks prior to the study
• Patients with an expected length of ICU stay shorter than 3 days
• Patients with a low probability of surviving the first 2 days after ICU admission
• Pregnancy and nursing

Trial design

500 participants in 2 patient groups

AKI

Description:

Patients developing AKI during the ICU stay

Treatment:

Other: Blood draw for measurement of MIF

No AKI

Description:

Matched controls not developing AKI during the ICU stay

Treatment:

Other: Blood draw for measurement of MIF